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Aim To assess the concentration of B-type natriuretic pep-
tide (BNP) as a predictor of heart failure in patients with 
acute ST elevation myocardial infarction (STEMI) who un-
derwent primary percutaneous coronary intervention (PCI) 
with successful and complete revascularization.
Methods Out of a total of 220 patients with acute STE-
MI admitted to the Sisters of Mercy University Hospital in 
the period January 1 to December 31, 2007, only patients 
with acute STEMI undergoing primary PCI who had single 
vessel disease and were successfully revascularized were 
included in the study. Selected patients had no history of 
myocardial infarction or heart failure and a normal or near-
normal left ventricular ejection fraction (≥50%) assessed by 
left ventriculography at admission. Only 58 patients met 
the inclusion criteria for the study. Out of those, 6 patients 
refused to participate in the study, and another 5 could not 
be followed up, so a total of 47 patients were evaluated. 
Blood samples were taken for measurement of BNP levels 
at admission, 24 hours later, and 7 days later. Patients were 
followed up for 1 year. The primary outcome was reduc-
tion in left ventricular ejection fraction (LVEF) to <50% af-
ter 1 year.
Results Patients who developed echocardiographic signs 
of reduced systolic function defined as LVEF<50% had sig-
nificantly higher values of BNP (≥80 pg/mL) at 24 hours 
(P = 0.001) and 7 days (P = 0.020) after STEMI and successful 
reperfusion. Patients who had BNP levels ≥80 pg/mL after 
7 days were 21 times more likely to develop LVEF<50 (odds 
ratio, 20.8; 95% confidence interval, 2.2-195.2; P = 0.008).
Conclusion BNP can be used as a predictor of reduced 
systolic function in patients with STEMI who underwent 
successful reperfusion and had normal ejection fraction at 
admission.
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Natriuretic peptides are peptides that are released from 
the heart in situations of pressure and volume overload of 
the ventricles. There are 3 types of natriuretic peptides: atri-
al natriuretic peptide, B-type natriuretic peptide (BNP), and 
C-type natriuretic peptide. Atrial natriuretic peptide is re-
leased predominantly from the atria, BNP from the ventri-
cles, and C-type natriuretic peptide from the endothelium 
(1-4). BNP is a 32-amino acid neurohormone synthesized 
in the form of pre-proBNP, which is first cleaved to proBNP 
and then to active BNP and inactive fragment NT-proBNP. 
Its serum levels are increased in left ventricular dysfunc-
tion, atrial fibrillation, acute myocardial ischemia (acute 
coronary syndromes, acute myocardial infarction), pulmo-
nary embolism, advanced age, renal dysfunction, etc (4). 
The actions of BNP include natriuresis, vasodilatation, inhi-
bition of renin-angiotensin-aldosterone axis, and inhibition 
of sympathetic nerve activity.
In the first hours of acute myocardial infarction, BNP is re-
leased as a result of ischemia and necrosis of myocardial 
cells. BNP then rises as a result of systolic and diastolic dys-
function and increased wall stress of the left ventricle (5).
Patients with acute ST elevation myocardial infarction 
(STEMI) who had higher levels of BNP have been shown 
to have worse prognosis (death, congestive heart failure, 
myocardial infarction, and no-reflow phenomenon) (5). 
Also, patients who died after the STEMI had significantly 
higher values of BNP (5).
We assessed the predictive value of BNP for heart failure in 
patients who underwent primary percutaneous coronary 
intervention (PCI) for acute STEMI with single-vessel dis-
ease and the optimal timing for the measurement of BNP. 
We included only patients with no previous known heart 
failure and normal or near-normal global left ventricular 
systolic function at admission (LV≥50%). To our knowledge, 
none of the previous studies evaluated BNP as predictor of 
heart failure in STEMI patients with previously normal LVEF 
who underwent successful reperfusion.
PaTieNTs aND MeTHoDs
Patients
From January 1 until December 31, 2007, we prospectively 
studied 220 patients with acute STEMI admitted to the Sis-
ters of Mercy University Hospital. Only the patients within 
12 hours from the onset of symptoms who underwent 
primary PCI, had only single-vessel disease, under-
went complete and successful revascularization (TIMI III 
flow and MBG III), and had normal or slightly reduced LVEF 
(≥50%) were included. Patients with cardiogenic shock, 
symptoms lasting more than 12 hours, significant dou-
ble-vessel, triple-vessel or left main disease, unsuccessful 
reperfusion, history of MI, and significant mitral regurgita-
tion were excluded from the study. Among a total of 220 
patients with STEMI admitted to our hospital during that 
period, only 58 met the inclusion criteria. Six patients re-
fused to participate in the study, so 52 patients were in-
cluded while another 5 patients were lost during the fol-
low-up (had a check up at another hospital). This left the 
final group of 47 patients (Figure 1). Signed informed con-
Figure 1.
Flowchart of the study. among 220 patients with acute myocardial inf-
arction, those with cardiogenic shock, symptoms lasting more than 12 
hours, significant double-vessel, triple-vessel, or left main disease, un-
successful reperfusion, history of myocardial infarction, and significant 
mitral regurgitation were excluded from the study (n = 162). Fifty eighth 
patients were eligible for the study. sTeMi – sT elevation myocardial in-
farction.
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sent for PCI and for participation in the study was obtained 
before angiography from all patients.
Clinical evaluation
Patients were admitted through the emergency depart-
ment, where standard history and physical status were 
taken. They were evaluated for onset and duration of 
pain, comorbidities, and risk factors. Vital signs and com-
plete physical status were also obtained. In 12 patients, 
lead electrocardiogram (ECG) was obtained and patients 
with STEMI were presented to the interventional cardiolo-
gist and taken to the catheterization laboratory for primary 
PCI. All patients were managed and treated according to 
European Society of Cardiology Guidelines for PCIs (6) and 
Croatian primary PCI network. Ethical approval of the study 
was obtained from the hospital Ethics Committee.
Blood sampling
Blood samples were taken for routine laboratory tests 
(complete blood count, creatinine, electrolytes, glucose, 
creatine kinase, lactate dehydrogenase, troponin T levels, 
prothrombin time and activated partial thromboplastin 
time, C reactive protein, and lipid profile), as well for the 
measurement of BNP levels. The hospital laboratory sets 
the normal value of BNP at <18.4 pg/mL. Blood samples 
were collected into a plastic tube (EDTA 1.5 mg/mL), and 
concentration of BNP was determined by an immunora-
diometric assay (SHIONORIA BNP in vitro test, CIS Bio In-
ternational, Gif-Sur-Yvette Cedex, France). BNP levels were 
measured at admission, 24 hours after the PCI, and 7 days 
after the PCI. Creatine kinase and lactate dehydrogenase 
levels were monitored until normalization.
angiography and PCi
Coronary angiography was performed by transfemoral ap-
proach. Patients received 300 mg of aspirin and 600 mg of 
clopidogrel before the procedure. They also received 3000-
5000 IU heparin bolus after arterial sheath placement and 
additional 3000-5000 IU heparin before the PCI (total of 
100 IU/kg). Before coronary angiography, left ventriculo-
gram was performed in all patients with 2 standard projec-
tions (right anterior oblique 30 and left anterior oblique 60) 
and LVEF was calculated. At this point, patients with signifi-
cantly reduced systolic function (LVEF<50%) or significant 
mitral regurgitation were excluded from the study. After vi-
sualizing of left and right coronary artery, provisional stent-
ing of culprit lesion on infarct related artery was done by 
standard techniques. Use of eptifibatide was decided by 
the operator. TIMI angiographic scale was used to deter-
mine the reperfusion of infarct related artery. During coro-
nary angiography, patients with reduced ejection fraction, 
more than single-vessel disease, and with unsuccessful re-
perfusion were excluded from the study (n = 162).
After the procedure, all patients were admitted to coronary 
care unit, received aspirin 100 mg and clopidogrel 75 mg 
daily and other standard concomitant therapy (beta block-
ers, ACE inhibitors, and statins) depending on clinical in-
dications. Patients received low molecular weight heparin 
during 3-5 days, starting 6 hours from the femoral artery 
sheath removal. Echocardiography was done in all patients 
by a standard protocol, 2-4 days after admission; ejection 
fraction was calculated using the methods by Simpson (7) 
and Teicholz (8). Diastolic dysfunction, segmental hypo- or 
akynesis, pulmonary hypertension, and the presence of 
mitral regurgitation were also recorded. Patients were dis-
charged from hospital 7-10 days after the admission and 
continued to receive aspirin 100 mg, clopidogrel 75 mg, 
beta blocker, statin, and ACE inhibitor.
Follow up
All patients were followed at 3, 6, and 12 months. Three 
months after the myocardial infarction clinical examina-
tion, laboratory tests and ECG stress test were done, and 6 
and 12 months after the discharge echocardiography and 
ECG stress tests were done.
end points
Primary end point at 12 months after the myocardial in-
farction was the reduction in ejection fraction to less than 
50%, with or without clinical signs and symptoms of heart 
failure.
statistical analysis
Smirnov Kolmogorov test was used to analyze data distri-
bution. According to these findings, appropriate tests were 
used in further analysis. Chi square test was used to analyze 
differences in frequencies of qualitative variables. To deter-
mine predictive values of BNP levels, binary logistic regres-
sion was performed. Ejection fraction after 12 months 
was used as the dependent variable (0 − ejection fraction 
≥50% and 1 − ejection fraction <50%). BNP levels ≥80 
pg/mL (0 hours, 24 hours, 7 days), age, sex, positive his-
tory of illness, and body mass index (BMI) were used 
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as predictor variables. P value lower than 0.05 was consid-
ered significant. SPSS for Windows, version 17.01 (SPSS Inc., 
Chicago, IL, USA) was used in all statistical procedures ex-
cept for receiver operating (ROC) analysis which was calcu-
lated using MedCalc for Windows, version 11.0 (MedCalc 
Software, Mariakerke, Belgium).
ResuLTs
At admission, all 47 patients had normal LVEF (≥55%), and 
all 47 patients underwent primary PCI with stent implanta-
tion (Table 1). Patients were divided in 2 groups depend-
ing on whether their BNP values were lower than 80 pg/
mL at admission, 24 hours, and 7 days. The cut-off point of 
BNP levels was set to 80 pg/mL, as described in previous 
studies (10,11). ROC curve analysis showed that values of 
BNP≥80 pg/mL had 60.0% sensitivity and 82.2% specific-
ity for predicting reduced ejection fraction after 12 months 
(Figure 2).
At admission, BNP was ≥80 pg/mL in only 8 patients, while 
in 39 patients it was lower than 80 pg/mL. After follow-up 
of 12 months, 4 patients out of 8 with BNP over 80 pg/
mL had LVEF<50%, and other 4 had LVEF≥50%. Among pa-
tients with BNP lower than 80 pg/mL (n = 39), 17 (43.5%) 
had reduced LVEF after 12 months. There was no signifi-
cant difference between the 2 groups (P = 0.740) (Table 2).
After 24 hours, there was the greatest number of patients 
with BNP levels higher than 80 pg/mL (n = 37), while there 
were 10 patients with BNP lower than 80 pg/mL. After 12 
months of follow-up, 2 patients with BNP levels lower than 
80 pg/mL had LVEF<50% (20.0%), while 19 patients of 37 had 
LVEF<50% (51.4%). The differences in the number of patients 
at different time intervals were not significant (P = 0.770).
After 7 days, there was statistical difference between 2 
groups. Eighteen patients had BNP levels higher than 80 
TaBLe 1. Clinical and demographic features of studied pa-
tients*
Characteristics No (%) of patients
age (mean±sD) 58.9 ± 10.3
sex:
male  35 (74.5)
female  12 (25.5)
Body mass index (mean±sD) 28.865 ± 4.318
















family history  57.44
hyperlipidemia  42.55
BNP levels (pg/mL):
at a admission  41.04 ± 50.23
24 h 164.93 ± 94.82
7 d 107.03 ± 137.14
TiMi flow:
at baseline 0.234 ± 0.427
after reperfusion     3
STENT 100
*abbreviations: LaD − left anterior descedening artery; 
aCx − circumflex artery; RCa − right coronary artery ; BNP − brain 
natriuretic peptide; TiMi − thrombolysis in myocardial infarction; sD 
– standard deviation.
†Killip class i-iV used for risk stratification of patients with myocardial 
infarction (9).
Figure 2.
Receiver operating characteristic (RoC) curve analysis for B-type natri-
uretic peptide (BNP) after 7 days as predictor of reduced ejection frac-
tion after 12 months. Criterion BNP ≥80 pg/mL after 7 days; sensitiv-
ity, 60.0% (95% confidence interval, 36.1-80.9); specificity, 82.2% (95% 
confidence interval, 60.6%-93.4%); area under the RoC curve=0.765; P 
(area=0.5) <0.001.
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pg/mL and 29 had levels lower than 80 pg/mL. In patients 
with elevated levels of BNP after 7 days, 13 (72.2%) had 
LVEF<50% after 12 months of follow-up and among 29 pa-
tients with BNP levels lower than 80 pg/mL after 7 days, 8 
had LVEF<50% (27.6%) (P = 0.003).
Also, at 12 months there were 21 patients with LVEF<50% 
and 26 patients with LVEF≥50%. The group with reduced 
ejection fraction had higher mean values of BNP at 0 
(P = 0.470), 24 hours, and 7 days with significant difference 
at 24 hours (P = 0.001) and 7 days (P = 0.020) (Table 3).
Using binary logistic regression, we found that patients 
with BNP levels ≥80 pg/mL after 7 days were 21 times 
more likely to develop EFLV<50 (odds ratio, 20.8; 95% con-
fidence interval, 2.2-195.2, P = 0.008). Also, patients with 
lower values of BMI were more likely to develop LVEF<50% 
(Table 4).
DisCussioN
We studied the value of BNP in predicting left ventricu-
lar systolic dysfunction in patients with STEMI and normal 
left ventricular systolic function at admission and success-
ful reperfusion. BNP levels were measured at 3 different 
time points (admission, 24 hours, and 7 days). Our study 
showed that that BNP in patients who underwent primary 
PCI due to STEMI with successful reperfusion could serve 
as a predictor of systolic dysfunction with LVEF<50% after 
12 months of follow-up. The risk of developing heart fail-
ure with reduced systolic function was higher in patients 
with elevated BNP levels after 24 hours and 7 days, with 
a significant increase at 7 days with a cut-off point of 80 
pg/mL. BNP levels ≥80 pg/mL after 7 days were found to 
be an independent risk factor for development of reduced 
ejection fraction after 12 months, when patients with BNP 
levels ≥80 pg/mL were 21 times more likely to have a re-
duced ejection fraction. Also, patients who developed re-
duced ejection fraction after 12 months had significantly 
higher mean values of BNP at 24 hours and 7 days. A limi-
tation of the study is a relatively small number of patients, 
so data should be interpreted with caution. Although we 
had a total of 220 patients with STEMI, only 58 met the in-
clusion criteria and in the end only 47 were evaluated. In 
the first 24 hours, natriuretic peptides are released from the 
myocardium in response to acute ischemia. Later, BNP is 
secreted due to myocardial stunning, left ventricular sys-
tolic, or diastolic dysfunction as was described in previous 
studies (4,5). Previous studies have also found that BNP lev-
els at admission could serve as predictor of short and long 
term mortality after STEMI, worse outcome as well as ‘’no 
reflow’’ phenomenon and impaired reperfusion (10,12-14). 
Also the relation between the level of BNP is associated 
with the infarct size and infarct mass assessed with car-
diac MR and echocardiography (15-17). Although all our 
patients had single vessel disease and angiographycally 
successful reperfusion, it is possible that patients who 
had elevated BNP levels after 7 days had impaired or 
delayed reperfusion and, therefore, higher risk of 
TaBLe 2. Difference in left ventricular ejection fraction (LVeF) 
after 12 months of follow-up in patients with brain natriuretic 
peptide (BNP) levels higher or lower than 80 pg/mL at admis-
sion, 24 h, and 7 days
LVeF at No. of patients with BNP (pg/mL)
time point ≤80 ≥80 Total P
admission: 39  8 47
<50 17  4 21 0.740
≥50 22  4 26
24 h: 10 37 47
<50  2 19 21 0.770
≥50  8 18 26
7 d: 29 18 47
<50  8 13 21 0.003
≥50 21  5 26
TaBLe 3. Median values of BNP at admission, 24 h, and 7 days 








0 h 47.19 ± 58.37 36.07 ± 43.14 0.457
24 h 212.93 ± 107.24 126.16 ± 62.01 0.001
7 d 164.60 ± 177.26 69.28 ± 81.56 0.020
*BNP – B-type natriuretic peptide: LVeF – left ventricular ejection 
fraction.
TaBLe 4. Binary logistic regression for prediction of reduced 
ejection fraction after 12 months*
Variables oR (95% Ci) P
BNP≥80 pg/mL at 0 h  0.10 (0.01-1.58) 0.101
BNP≥80 pg/mL at 24 h 10.40 (0.73-147.13) 0.083
BNP≥80 pg/mL at 7 d 20.76 (2.21-195.16) 0.008
Age (years)  0.98 (0.90-1.06) 0.605
Male sex  0.29 (0.04-2.18) 0.227
BMI  0.76 (0.58-0.99) 0.042
Positive history  0.39 (0.07-2.25) 0.289
*abbreviations: oR − odds ratio, Ci − confidence interval; BNP − B-type 
natriuretic peptide; BMi − body mass index.
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left ventricular remodeling and developing left ventricu-
lar systolic dysfunction. This study showed that BNP could 
serve as a predictor of reduced systolic function in patients 
who had normal systolic function at admission, single-ves-
sel disease, and were successfully revascularized during 
the primary PCI. Therefore, in this population BNP could be 
used to recognize patients who are at high risk for devel-
oping heart failure and should be clinically followed more 
often than others. Due to a relatively small number of pa-
tients, more studies are needed to confirm the prognostic 
value of the BNP for reduced systolic function after percu-
taneous coronary intervention.
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